Synairgen Company Description

Synairgen plc discovers and develops drugs for respiratory diseases.

It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses.

Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Synairgen plc

Country	United Kingdom
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	34
CEO	Joseph Colliver

Contact Details

Address: Mailpoint 810 Southampton, SO16 6YD United Kingdom
Phone	44 23 8051 2800
Website	synairgen.com

Stock Details

Ticker Symbol	SYGGF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00B0381Z20
SIC Code	2836

Key Executives

Name	Position
Joseph Tregonning Colliver F.C.A.	Chief Executive Officer and Executive Director
Prof. Stephen T. Holgate CBE, M.D.	Co-Founder and Member of Scientific Advisory Board
Dr. Mark Parry-Billings Ph.D.	Executive Chairman
Prof. Donna Davies	Co-Founder and Member of Scientific Advisory Board
Prof. Ratko Djukanovic	Co-Founder and Member of Scientific Advisory Board
Andy Lee	Finance Director
Dr. Gareth E. Walters Ph.D.	Chief Regulatory Officer
Jody Brookes	Senior Vice President and Head of Clinical Operations
Dr. Marcin Mankowski M.D.	CMO and Head of Scientific Affairs
Simon William Holden Esq.	Company Secretary